Based on OS analysis and PFS analysis, we performed several subgroup analyses from 5 aspects, cancer type (NSCLC, RCC, HCC, EC, and MEL), ICI therapy type (PD-1, PD-L1), ATB window (−60 days, +30 days), ATB class (broad-spectrum ATB class) and ECOG score (2–5 vs 0–1). This evidence concerns the gene CD274 and hepatocellular carcinoma.